We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tissue Model Used to Show Molecular Basis for Infection

By LabMedica International staff writers
Posted on 27 Apr 2017
A team of molecular microbiologists has explained the mechanism by which Neisseria gonorrhoeae, the bacterium that causes the urinary tract infection gonorrhea, invades and colonizes female genital tissues.

Since humans are the only host for Neisseria gonorrhoeae (GC), a lack of a human infection model has been a major obstacle to understanding the process of GC infection.

In the current study, investigators at the University of Maryland used a human tissue explant model to examine the mechanism by which GC infect the human endocervix, the primary site for GC infection in women.

They reported in the April 13, 2017, online edition of the journal PLOS Pathogens that GC penetrate into the human endocervix by activating the actin motor myosin protein and epithelial shedding. More...
Myosin activation causes the disruption of the endocervical epithelial barrier by inducing apical junction disassembly and epithelial cell shedding, allowing GC penetration into the human endocervical tissue. GC bacteria activate myosin by inducing calcium ion-dependent phosphorylation of the myosin light chain.

The investigators stated that study represented the first laboratory demonstration of the penetration of N. gonorrhoeae into the human endocervix and provided new insights into the molecular processes that underlie gonorrhea infection.


New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.